CompletedNCT05004896
Repeated ketamine infusions for treatment-resistant depression in people with bipolarity
About this title
Ketamine for Treatment-Resistant Bipolar Disorder
Read the official source — NCT05004896Medication studyAges 21–65Canada
Understand this study
Who was this study for?
Listed age limits: 21 years to 65 years.
- Listed locations
- Toronto and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: July 4, 2022
- Recruitment status
- Completed
- Enrollment listed in the registry
- 71
- Sponsor
- Joshua Rosenblat
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Canada
- Age range
- From 21 Years to 65 Years
- Official registry ID
- NCT05004896
- Official title
Show the full official title
Repeated Ketamine Infusions for Treatment-Resistant Bipolar Disorder: A Randomized, Double-blind, Midazolam-controlled, Phase II Clinical Trial
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Toronto · Whitby
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Joshua Rosenblat.
Did this study involve medication?
Yes. The study involved medication, including Ketamine Hydrochloride and Midazolam Hydrochloride.
Who was this study for?
Listed age limits: 21 years to 65 years.
